US6852700B1ExpiredUtility

Colostrinin, and uses thereof

40
Assignee: LUDWIG HIRZFELD INST OF IMMUNOPriority: Oct 3, 1996Filed: Oct 3, 1997Granted: Feb 8, 2005
Est. expiryOct 3, 2016(expired)· nominal 20-yr term from priority
Inventors:Marin JanuszJozef LisowskiAnna Dubowska-Inglot
A61P 37/00A61P 37/02A61P 7/00A61P 37/04A61P 25/28A61P 25/16A61P 31/04A61P 31/12A61P 25/00A61P 25/18A61P 25/22A61P 3/02A61P 25/30A61P 25/24C07K 14/47A23V 2002/00A23V 2200/324A61K 38/00A23L 33/40A23L 33/18A23L 33/19
40
PatentIndex Score
11
Cited by
25
References
32
Claims

Abstract

The use of Colostrinin as a medicament, particularly in the treatment of chronic disorders of the central nervous system and the immune system.

Claims

exact text as granted — not AI-modified
1. A method of treating a human patient afflicted with dementia comprising administering a composition comprising a therapeutic unit of Colostrinin in isolated form to the human patient about one or two times per day for a predetermined period of time. 
     
     
       2. The method according to  claim 1  wherein the Colostrinin is non-ovine Colostrinin. 
     
     
       3. The method according to  claim 1 , wherein the therapeutic unit of Colostrinin is in the range of about 25 to 1000 micrograms. 
     
     
       4. The method according to  claim 1  wherein the therapeutic unit of Colostrinin in isolated form is administered to the patient about one or two times each day for a first period of time, followed by a second period of time when no Colostrinin is administered. 
     
     
       5. The method according to  claim 4  wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks. 
     
     
       6. The method according to  claim 4  wherein a cycle of administering Colostrinin in isolated form for a first period of time followed by a second period of time when Colostrinin is administered is repeated at least once. 
     
     
       7. A method of treating a human patient afflicted with Alzheimer's Disease comprising administering a composition comprising a therapeutic unit of Colostrinin in isolated form to the human patient about one or two times per day for a predetermined period of time. 
     
     
       8. The method according to  claim 7 , wherein the Colostrinin is non-ovine Colostrinin. 
     
     
       9. The method according to  claim 7 , wherein the therapeutic unit of Colostrinin is in the range of about 25 to 1000 micrograms. 
     
     
       10. The method according to  claim 7  wherein the therapeutic unit of Colostrinin in isolated form is administered to the patient about one or two times each day for a first period of time, followed by a second period of time when no Colostrinin is administered. 
     
     
       11. The method according to  claim 10  wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks. 
     
     
       12. The method according to  claim 10  wherein a cycle of administering Colostrinin in isolated form for a first period of time followed by a second period of time when Colostrinin is administered is repeated at least once. 
     
     
       13. A method of treating a human patient afflicted with dementia comprising administering up to two therapeutic units of Colostrinin in isolated form to the human patient per day, wherein each therapeutic unit of Colostrinin is in the range of about 25 to 1000 micrograms. 
     
     
       14. The method according to  claim 13  wherein the up to two therapeutic units of Colostrinin in isolated form are administered to the patient every day or every other day for a first period of time followed by a second period of time when no therapeutic units of Colostrinin are administered to the human patient. 
     
     
       15. The method according to  claim 14  wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks. 
     
     
       16. The method according to  claim 15  wherein a cycle of administering Colostrinin in isolated form for the first period of time followed by the second period of time when Colostrinin is administered is repeated at least once. 
     
     
       17. The method according to  claim 13  wherein the Colostrinin is formulated for oral administration. 
     
     
       18. A method of treating a human patient afflicted with Alzheimer's Disease comprising administering up to two therapeutic units of Colostrinin in isolated form to the human patient per day, wherein each therapeutic unit of Colostrinin is in the range of about 25 to 1000 micrograms. 
     
     
       19. The method according to  claim 18  wherein the up to two therapeutic units of Colostrinin in isolated form are administered to the patient every day or every other day for a first period of time followed by a second period of time when no therapeutic units of Colostrinin are administered to the human patient. 
     
     
       20. The method according to  claim 19  wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks. 
     
     
       21. The method according to  claim 20  wherein a cycle of administering Colostrinin in isolated form for the first period of time followed by the second period of time when Colostrinin is administered is repeated at least once. 
     
     
       22. The method according to  claim 18  wherein the Colostrinin is formulated for oral administration. 
     
     
       23. A method of treating a human patient afflicted with dementia comprising administering up to two therapeutic units of a nonapeptide having the amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO: 1) in isolated form to the human patient per day, wherein each therapeutic unit of the nonapeptide is in the range of about 25 to 1000 micrograms. 
     
     
       24. The method according to  claim 23  wherein the up to two therapeutic units of the nonapeptide in isolated form are administered to the patient every day or every other day for a first period of time followed by a second period of time when no therapeutic units of the nonapeptide are administered to the human patient. 
     
     
       25. The method according to  claim 24  wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks. 
     
     
       26. The method according to  claim 25  wherein a cycle of administering the nonapeptide in isolated form for the first period of time followed by the second period of time when the nonapeptide is administered is repeated at least once. 
     
     
       27. The method according to  claim 23  wherein the nonapeptide is formulated for oral administration. 
     
     
       28. A method of treating a human patient afflicted with Alzheimer's Disease comprising administering up to two therapeutic units of a nonapeptide having the amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO: 1) in isolated form to the human patient per day, wherein each therapeutic unit of the nonapeptide is in the range of about 25 to 1000 micrograms. 
     
     
       29. The method according to  claim 28  wherein the up to two therapeutic units of the nonapeptide in isolated form are administered to the patient every day or every other day for a first period of time followed by a second period of time when no therapeutic units of the nonapeptide are administered to the human patient. 
     
     
       30. The method according to  claim 29  wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks. 
     
     
       31. The method according to  claim 30  wherein a cycle of administering the nonapeptide in isolated form for the first period of time followed by the second period of time when the nonapeptide is administered is repeated at least once. 
     
     
       32. The method according to  claim 28  wherein the nonapeptide is formulated for oral administration.

Join the waitlist — get patent alerts

Track US6852700B1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.